The Board of Queensland Bauxite Limited (ASX:QBL) is delighted to announce that the ASX has approved the Company's Announcement to be released. The Company intends to release the announcement on Thursday 21 June 2018. QBL will recommence trading on the ASX following the release of the Announcement.
Nanollose Limited (ASX:NC6) is pleased to announce that, following the recent successful pilot scale production of its Plant-Free NullarborTM fibre, Mr Gary Cass will increase his involvement in the Company's research and development. From 11 June 2018 Mr Cass will commence a full-time executive role within Nanollose and transition from non-executive director to executive director of the Company.
Oventus Medical Ltd (ASX:OVN) is pleased to attach a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors this morning at the Thorney Sydney Investment Forum.
Oventus Medical Ltd (ASX:OVN) is pleased to announce positive interim data being presented today in a lecture at Macquarie University on a group of hard-to-treat obstructive sleep apnoea patients, who were studied in a sub-group as part of the ongoing "NeuRA Sydney study".
Nanollose Limited (ASX:NC6) is pleased to advise that it has received valid applications from Shareholders for 14,505,733 Options pursuant to the non-renounceable 1:4 entitlement option offer announced on 16 April 2018.
Nanollose Limited (ASX:NC6) is pleased to announce it has successfully manufactured its world first plant-free viscose-rayon fibre (NullarborTM) on a pilot scale. As a result of this increased scale, the Company has been able to create fabric for the first time, marking a significant breakthrough for Nanollose and the textile industry.
Oventus Medical Ltd (ASX:OVN) is pleased to announce the results of the OVEN-003 clinical trial study being conducted in Brisbane by the company, a randomised controlled clinical trial examining the treatment outcomes of oral appliance therapy with and without 'Oventus Airway Technology'.
